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Abstract
Background: To assess the impact of luteal phase support on the expression of estrogen receptor (ER) alpha and
progesterone receptors B (PR-B) on the endometrium of oocyte donors undergoing controlled ovarian
hyperstimulation (COH).
Methods: A prospective, randomized study was conducted in women undergoing controlled ovarian
hyperstimulation for oocyte donation. Participants were randomized to receive no luteal support, vaginal
progesterone alone, or vaginal progesterone plus orally administered 17 Beta estradiol. Endometrial biopsies were
obtained at 4 time points in the luteal phase and evaluated by tissue microarray for expression of ER alpha and
PR-B.
Results: One-hundred and eight endometrial tissue samples were obtained from 12 patients. No differences were
found in expression of ER alpha and PR-B among all the specimens with the exception of one sample value.
Conclusions: The administration of progesterone during the luteal phase of COH for oocyte donor cycles, either
with or without estrogen, does not significantly affect the endometrial expression of ER alpha and PR.
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Background
The spatial and temporal expression of specific extracel-
lular matrix (ECM) proteins and adhesion molecule
genes creates a profile that is crucial for successful
embryo implantation [1,2]. The effect of exogenous hor-
mone administration on these complex hormonal signal-
ing pathways is not totally elucidated. Some investigators
purport that controlled ovarian hyperstimulation (COH)
protocols inevitably lead to lack of synchrony between
the development and maturation of the endometrium
and the time of oocyte retrieval or “ovulation” [3,4].
However, conflicting information exists as to whether
COH does in fact lead to a clinically significant degree of
endometrial lack of synchrony [5-8].
Ovarian stimulation protocols for IVF have been fre-
quently associated with luteal phase deficiency and poor
implantation rates [3,4]. Additionally, there are some
data showing that, in GnRH agonist/HMG stimulated
cycles, lack of supplementation with exogenous proges-
terone (P) results in impaired P bioavailability [9,10]. For
this reason, luteal phase support is customarily used to
improve endometrial structure and histology thus facili-
tating the implantation process. P is accepted as the pre-
ferred agent for luteal phase support and is administered
orally, intramuscularly, or vaginally [11,12].
Animal and human studies have shown that estradiol
(E2) serves a critical role in endometrial development
compatible with successful pregnancy [13,14]. Addition-
ally, data have shown that, in some women, E2 levels
fall in the mid luteal phase of an IVF cycle [14]. This
finding led to the incorporation of 17b-E2 or E2 valerate
into many ART programs for luteal phase support [3,4].
Studies evaluating the concept of E2 addition during
the luteal phase have thus far failed to show any benefit
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any medium, provided the original work is properly cited.or led to inconclusive results [3,4,10,15]. However, data
regarding the effect of luteal phase support in IVF cycles
are limited and there is still not a universal consensus
regarding optimal supplementation during the luteal
phase [12,16,17].
In the present study, we investigated the effects of two
commonly used luteal phase support protocols (P alone
and P plus E2), on the expression of the E2 Receptor a
(ERa) and the P receptor B (PR-B) in the human endo-
metrium following ovarian stimulation with a gonado-
tropin/GnRH antagonist protocol.
Methods
Clinical trial
The study was approved by the Johns Hopkins Hospital
Institutional Review Board.
Women undergoing COH for oocyte donation in an
outpatient assisted reproductive technology (ART) clinic
were enrolled over the period of 1 year. A power analysis
was not performed prior to initiating the study. Rather,
all eligible women possible were approached regarding
study participation. Women from 21-29 yr of age were
eligible as oocyte donors. The selection process included
a thorough questionnaire and psychological evaluation of
the potential donors followed by a detailed physical
examination and consultation to discuss the process of
oocyte donation by a physician member of the group.
T h er i s k so ft h ep r o c e d u r ew e re discussed in detail, and
written informed consents were obtained. All donors
were screened for sexually transmitted diseases as well as
for genetic conditions in accordance with the recommen-
dations of the American Society for Reproductive Medi-
cine [18]. Women with a body mass index exceeding 28
kg/m
2, history of pelvic inflammatory disease, sexually
transmitted diseases, reproductive tract pathology, or
other systemic diseases or conditions were excluded. No
women included in this study had any known endocron-
logic abnormality including polycystic ovarian syndrome.
At the time of their initial visit, they received a detailed
explanation of the study protocol with particular empha-
sis on the risks associated with the endometrial biopsy
and the use of steroids during their luteal phase. A writ-
ten informed consent was obtained at that time.
Oocyte donors were stimulated with a GnRH antago-
nist protocol. Briefly, all donors had a baseline measure-
ment of FSH and E2 serum concentrations on the second
day of their menstrual cycles after the discontinuation of
oral contraceptive pills. In addition, a transvaginal sono-
gram was performed to rule out early follicular develop-
ment and any anatomic anomalies. Providing that serum
FSH was less than 10 mIU/ml and E2 was less than 60
pg/ml, ovarian stimulation was initiated with 225 IU
recombinant FSH (Follitropin Alfa, Gonal-F; Serono
Laboratories, Norwell, MA). A daily evening dose of
ganirelix acetate (Antagon; Organon, West Orange, CA),
0.25 mg sc, was started either 6 d after the initiation of
gonadotropins or at the time of identification of a leading
follicle with mean diameter more than 13 mm and con-
tinued through the day of human chorionic gonadotropin
(hCG). Thereafter, the dose of gonadotropins was
adjusted in a step-down fashion according to follicular
development by serial transvaginal ultrasound and serum
E2 response. When at least three follicles reached a mean
diameter of 18 mm, ovulation was triggered with a single
im dose of 10,000 IU hCG (Profasi; Serono) or 20 U of a
GnRH agonist administered in two doses 24 h apart.
Transvaginal oocyte retrieval was performed under iv
sedation 34-36 h after hCG or the initial dose of GnRH
agonist.
On the day of oocyte retrieval, the study participants
were randomized into three treatment categories: The
“none” group did not receive any luteal phase support;
the “P” group received micronized P in the form of vagi-
nal suppositories (200 mg every 6 h starting from the day
after retrieval); the “P+E ” group received a daily oral
dose of 2 mg 17b-E2 in addition to the micronized P.
(Figure 1) Up to that point, all donors had been stimu-
lated according to the same protocol and had received a
comparable amount of medication. An endometrial
biopsy on the day of oocyte retrieval was performed on
all study participants to define a baseline status for the
endometrium.
Endometrial biopsies were performed using a Pipelle
catheter (Unimar, Wilton, CT) on the day of oocyte
retrieval (cycle day [CD] 14 of the benchmark cycle) and
then 3, 5, and 10 days after oocyte retrieval correspond-
ing to ideal cycle days 17, 19, and 24. At least 2-4 endo-
metrial biopsies were obtained from each donor. The
tissue in the endometrial samples were identified as
either luminal epithelium, the surface epithelium lining
the uterine cavity, glandular epithelium, or stromal tis-
sue. The specimens were then fixed in 10% formalin,
and subsequently embedded into paraffin for tissue
microarray sectioning.
Microarray analysis
Tissue microarrays (TMA) were assembled from paraffin
embedded endometrial tissues in a 1.5-mm diameter for
each tissue sample. Three representative tissue samples
were obtained for each specimen. The arrays encom-
passed 108 tissue cores derived from 12 donors (Table 1).
All tissue cores were sectioned in 5-μmt h i c k n e s sa n d
affixed to the TMA slides. (Figure 2) The expression of
ERa and PR-B were examined using Confirm antiER
(6F11) and Confirm anti-PR [16] mouse monoclonal
antibodies (Ventana Medical Systems Inc, Tucson, Ari-
zona) directed against the human ER and PR molecules.
The tissue sections were then incubated with biotinylated
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ing was detected through interaction of avidin-biotin
perioxidase (ABC) complex with biotin-conjugated sec-
ondary antibody using a Ventana DAB Detection Kit
(Ventana- Biotek Solutions, Tucson, AZ). Isotype-specific
irrelevant monoclonal antibody MiTF, generated against
the human microthalmia transcription factor in mela-
noma, was used as a primary antibody for a negative con-
trol [19]. Slides were subsequently counterstained with
hematoxylin. The intensity of immunostaining was
Figure 1 Study design. This figure outlines the design of the study. The baseline endometrial biopsy is shown at the top of the graph. The 3
arms of the study are then shown and described in each of 3 boxes.
Table 1 Endometrial progesterone receptor B expression in different luteal phase support groups
Group None Group P Group P+E P Value
H score (mean score)
CD 14 Luminal 7.6 (n = 4) 5.8 (n = 4) 7.9 (n = 4) 0.60
Glandular 9.5 (n = 4) 7.0 (n = 4) 6.4 (n = 4) 0.49
Stroma 6.9 (n = 4) 6.3 (n = 4) 8.0 (n = 4) 0.75
CD17 Luminal 3.8 (n = 3) 9.3 (n = 3) 4.4 (n = 3) 0.04
Glandular 6.7 (n = 3) 8.3 (n = 3) 3.3 (n = 3) 0.09
Stroma 6.8 (n = 3) 7.4 (n = 3) 5.1 (n = 3) 0.63
CD19 Luminal 4.8 (n = 3) 5.0 (n = 2) 5.1 (n = 3) 0.99
Glandular 4.5 (n = 3) 6.8 (n = 2) 5.6 (n = 3) 0.71
Stroma 5.8 (n = 3) 6.3 (n = 2) 5.0 (n = 3) 0.85
CD24 Luminal 3.0 (n = 2) 4.7 (n = 2) 7.0 (n = 3) 0.1 9
Glandular 3.5 (n = 2) 8.0 (n = 2) 4.8 (n = 3) 0.13
Stroma 5.8 (n = 2) 4.5 (n = 2) 6.0 (n = 3) 0.78
This table shows the H score for the Progesterone Receptors evaluated in this study. Statistical differences, at a level of ≤ 0.05, between the H score values for
the various groups (natural, Estrogen supported, and Estrogen and Progesterone supported) are also provided and H score values that significantly differ
between groups are bolded.
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[20,21]. Statistical analysis was performed using the
Mann-Whitney U test and Student t test when appropri-
ate using statistical package SPSS (Chicago, IL). Signifi-
cance was determined by a P value of ≤ 0.05.
Results and discussion
Endometrial biopsies were obtained from 12 oocyte
donors, randomized into 3 groups of 4 patients each.
T h e r ew e r en od i f f e r e n c e si nt h ea g e( a v e r a g eo f2 4 . 1±
1.0) or BMI (average of 21.1 ± 0.6 kg/m2). There were
no significant differences among the donors regarding
serum hormone profiles. No difference was found in
baseline laboratory values, including follicle stimulating
hormone (FSH) and E2 levels on CD#2, or the total
injectable medications (number of FSH ampoules and
dose of Ganirelix Acetate) used among the groups. Peak
serum E2 levels ranged from 1,817 pg/ml to 2,547 pg/
ml with no differences among the 3 groups (p = 0.378).
Immediately prior to oocyte retrieval, transvaginal ultra-
sound measurement of the endometrial lining of all
patients ranged between 9 and 11 mm and did not differ
among the groups. No difference was noted in the num-
b e ro fo o c y t e sr e t r i e v e d( r a n g eo f1 4t o1 9 )a m o n gt h e
study groups (p = 0.367).
No difference was found in the expression of the ERa
and PR between the “None”, “P”, and “P+E ” groups in all
but one time point in luminal endometrium,. There were
no differences in ERa values noted among all groups eval-
uated at all biopsy time points. The only significant differ-
ence in PR-B expression was observed on CD 17 in the
luminal epithelium of endometrium (Table 1). In this case,
the “P” group showed increased PR-B expression as com-
pared to the “none” or “P+E ” groups at a level of p =
0.04 in the luminal endometrium. However, even in this
group, there was no difference noted in PR-B expression
in the glandular and stromal endometrium between the
groups. This single difference is likely due to chance as the
study sample size was small. The difference could not be
explained by other clinical parameters, as all women were
without medical illness or other pathology prior to and
during the study.
E2 is well accepted to be a critical component of endo-
metrial development and pregnancy in both animal and
human models [13,15]. Some studies have shown that, in
some women, E2 levels may drop during the luteal phase
of an IVF cycle [14]. However, the supplementation to P
for luteal support with exogenous E2 in IVF cycles has
generally failed to affect significantly ultimate pregnancy
rates [3,4]. Our data supports these clinical findings, as we
did not find an effect on ERa and PR-B expression when
exogenous E2 was added to luteal phase support.
This study evaluated the endometrial expression of PR-
B. There are 2 distinct isoforms of PR (A and B) [22,23].
PR-B, which has an additional 164 amino acids at its
amino terminus, expression results in a stimulatory effect
on P target genes [23]. ERa and PR-B have stimulator
effects on stromal, glandular, and luminal endometrium
[24]. In the natural cycle, PR-B expression increases in
the luminal epithelium and in the stroma during the pro-
liferative phase and then remains high well into the
secretory phase [24]. However, in the glandular epithe-
lium many studies have shown a decline in PR-B expres-
sion during the late secretory phase immediately prior to
menses [24]. Furthermore, in the natural cycle, P has
been shown to have a down-regulatory effect on PR-B.
This study was primarily interested in the effect of possi-
ble downregulation of the PR-B receptor in response to
exogenous P and E2 exposure. In the IVF setting, and
with luteal support, we did not observe a down regulation
of PR-B expression in the late luteal phase. PR-A actually
suppresses PR-B expression. In the future, similar studies
should consider evaluating the expression of PR-A. Spe-
cifically, PR-A expression in glandular epithelium has
been documented to be associated with endometrial
Figure 2 Representative microarray slide. This picture shows the
tissue cores from the samples affixed to the tissue microarray slides
used in this study.
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future studies may enhance the findings of this and other
studies evaluating the effect of exogenous horomones on
endometrial function.
A chief limitation of this study is the low number of
oocyte donors included in the analysis. This is likely a
consequence of the difficulty in recruiting women agree-
able to participate in a study requiring inconvenient fol-
low up appointments and an invasive procedure
(endometrial biopsy). The low number of participants in
this study could have led to spurious results. Indeed, it is
possible that larger sample sizes could have identified dif-
ferences in these various populations. However, we could
not detect trends in the data that would suggest that
such differences would have been found with increased
sampling size. Certainly future studies with larger num-
bers of participants would help to further assess the
results of this study.
Endometrial receptivity is vital to the process of
implantation. Thus investigators have begun to study in
detail the complex signaling cascades necessary for endo-
metrial development and their responses to exogenous
hormonal manipulation [26]. Luteal phase hormonal sup-
port is almost universally used in IVF cycles to enhance
implantation of transferred embryos [27]. In this report,
we have demonstrated that the administration of vaginal
P, with and without E2, does not appear to significantly
affect PR expression in the endometrium in all but one
time point in luminal epithelium. We could not identify
any plausible explanation, based on either background
research or demographic characteristics of the patients in
this trial, to reconcile the presence of this outlier result.
Conclusions
Our observation is reassuring, supporting the use of luteal
phase support with P, as this practice has no deleterious
effect on the expression of PR in the uterine endometrium.
Indeed, it would not be unreasonable to expect that exo-
genous P administration could lead to a downregulation of
uterine PR receptors. Whether the addition of E2 to the
regimen has any additional effect needs further investiga-
tion. Further studies will undoubtedly delineate the endo-
metrial changes induced through COH cycles. The results
of this study are limited in evaluating the possible adverse
effects of the hormone therapies described. As the women
evaluated in this study were all oocyte donors and did not
undergo uterine transfer of an embryo, the effect of these
medications on a pregnancy, based on our data alone, is
not possible to quantify. Furthermore, an intrauterine preg-
nancy would likely change the endometrial and hormonal
environment and thus compromise the application of
our results in pregnant patients. However, our results are
reassuring given that, in the oocyte donor population,
down regulation of ERa and PRB was not observed with
exogenous hormone luteal support. Understanding the
relationships between COH/luteal support and endometrial
maturation can lead to further refinement and optimization
of IVF protocols.
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